Associate Professor Gregory Babcock
Associate Professor Babcock earned his PhD from Tufts University and did postdoctoral research at the Dana Farber/Harvard Cancer Institute. He currently serves as the Deputy Director of Product Discovery for MassBiologics at UMMS, overseeing research activities from initial conception of ideas for antibody development projects to the development of manufacturing-quality cell lines that express lead candidate monoclonal antibodies. This work involves cloning human, viral and bacterial antigens and expressing these antigens in both mammalian- and bacterial-based systems in the quantities required for both immunization and in vitro/in vivo assays. He also oversees developing novel in vitro assays to determine the activity of developed human monoclonal antibodies. Targets for antibody development have included SARS CoV, rabies virus, hepatitis C virus, tetanus toxin, and anti-SOD1 antibodies for treating ALS. He holds four patents for monoclonal antibodies.
Professor Mark Klempner
Professor Klemper earned his M.D. from Cornell University Medical College and taught at Tufts University School of Medicine and Boston University School of Medicine before joining UMMS. He has consulted for the National Institutes of Health, the U.S. Navy Medical Center, and the Charles Stark Draper Laboratory, and has served as the Associate Provost for Research and the Director of the National Emerging Infectious Disease Laboratories at Boston University Medical Center. He is currently the Executive Vice Chancellor of MassBiologics at UMMS. His research interests include normal and abnormal leukocyte (phagocyte) function, vector-host-pathogen interactions, molecular pathogenesis of bacterial infections, pathogenesis of Lyme disease, vaccine development and immune senescence, proteomics-technology development and biomedical applications, and sensor technology development. Over the course of his career he has received multiple grants from NIH, CDC, the U.S. Army, the National Space Biomedical Research Institute, and many private pharmaceutical laboratories.